Glargine trial promising for Mylan, Biocon
18 September 2014 | News | By BioSpectrum Bureau
Glargine trial promising for Mylan, Biocon
(Photo Courtesy: www.liferaftgroup.org)
Glargine was developed by India's Biocon which was out-licensed to Mylan for further development.
According to Mylan, the trials have been initiated in August 2014 and is expected to culminate in June 2016.
The market for this drug is expected to be $3-4 billion worldwide.
